Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder

Neuropsychopharmacology

Volumn 31, Issue 12, 2006, Pages 2739-2747

  Lohoff, Falk W ^a,d   Dahl, John P ^a   Ferraro, Thomas N ^a   Arnold, Steven E ^a   Gallinat, Jürgen ^b   Sander, Thomas ^c   Berrettini, Wade H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Association; Bipolar disorder; Linkage; Schizophrenia; SLC18A1; VMAT1

Indexed keywords

MESSENGER RNA; PROLINE; SERINE; THREONINE; VESICULAR MONOAMINE TRANSPORTER 1;

ADULT; ARTICLE; BIPOLAR I DISORDER; CENTRAL NERVOUS SYSTEM; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MAPPING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AMINO ACID SEQUENCE; BIOGENIC MONOAMINES; BIPOLAR DISORDER; BRAIN CHEMISTRY; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 8; DNA MUTATIONAL ANALYSIS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; INTRONS; MALE; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 33751083313     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301196     Document Type: Article

References (69)

1. Bakker SC, Hoogendoorn ML, Selten JP, Verduijn W, Pearson PL, Sinke RJ et al (2004). Neuregulin 1: genetic support for schizophrenia subtypes. Mol Psychiatry 9: 1061-1063.
2. Benoy IH, Elst H, Van der Auwera I, Van Laere S, van Dam P, Van Marck E et al (2004). Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer 91: 1813-1820.
3. Berrettini W (2003). Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am J Med Genet C Semin Med Genet 123: 59-64.
4. Berrettini W (2004). Bipolar disorder and schizophrenia: convergent molecular data. Neuromolecular Med 5: 109-117.
5. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G et al (1998). Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 20: 70-73.
6. Blumberg HP, Kaufman J, Martin A, Charney DS, Krystal JH, Peterson BS (2004). Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann NY Acad Sci 1021: 376-383.
7. Brzustowicz LM, Honer WG, Chow EW, Little D, Hogan J, Hodgkinson K et al (1999). Linkage of familial schizophrenia to chromosome 13q32. Am J Hum Genet 65: 1096-1103.
8. Cheng R, Juo SH, Loth JE, Nee J, Iossifov I, Blumenthal R et al (2006). Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry 11: 252-260.
9. Cichon S, Schumacher J, Muller DJ, Hurter M, Windemuth C, Strauch K et al (2001). A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. Hum Mol Genet 10: 2933-2944.
10. Cordeiro ML, Gundersen CB, Umbach JA (2002). Lithium ions modulate the expression of VMAT2 in rat brain. Brain Res 953: 189-194.
11. Cordeiro ML, Gundersen CB, Umbach JA (2004). Convergent effects of lithium and valproate on the expression of proteins associated with large dense core vesicles in NGF-differentiated PC12 cells. Neuropsychopharmacology 29: 39-44.
12. Cordeiro ML, Umbach JA, Gundersen CB (2000). Lithium ions up-regulate mRNAs encoding dense-core vesicle proteins in nerve growth factor-differentiated PC12 cells. J Neurochem 75: 2622-2625.
13. Corvin AP, Morris DW, McGhee K, Schwaiger S, Scully P, Quinn J et al (2004). Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the neuregulin-1 locus. Mol Psychiatry 9: 208-213.
14. Craddock N, Jones I (1999). Genetics of bipolar disorder. J Med Genet 36: 585-594.
15. Craddock N, Owen MJ (2005). The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry 186: 364-366.
16. DaSilva JN, Carey JE, Sherman PS, Pisani TJ, Kilbourn MR (1994). Characterization of [11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl Med Biol 21: 151-156.
17. 11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter. Appl Radiat Isot 44: 1487-1489.
18. Dick DM, Foroud T, Flury L, Bowman ES, Miller MJ, Rau NL et al (2003). Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet 73: 107-114.
19. Duan J, Martinez M, Sanders AR, Hou C, Krasner AJ, Schwartz DB et al (2005). Neuregulin 1 ( NRG1 ) and schizophrenia: analysis of a US family sample and the evidence in the balance. Psychol Med 35: 1599-1610.
20. Dudbridge F (2003). Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25: 115-121.
21. Eastwood SL (2004). The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame? Int Rev Neurobiol 59: 47-72.
22. Eells JB (2003). The control of dopamine neuron development, function and survival: insights from transgenic mice and the relevance to human disease. Curr Med Chem 10: 857-870.
23. Eiden LE, Schafer MK, Weihe E, Schutz B (2004). The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 447: 636-640.
24. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996). Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93: 5166-5171.
25. Fallin D, Schork NJ (2000). Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet 67: 947-959.
26. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N et al (2004). Assessing the impact of population stratification on genetic association studies. Nat Genet 36: 388-393.
27. Green EK, Raybould R, Macgregor S, Gordon-Smith K, Heron J, Hyde S et al (2005). Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry 62: 642-648.
28. Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R, Mankoo BS et al (2001). Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. Am J Hum Genet 68: 661-673.
29. Hansson SR, Hoffman BJ, Mezey E (1998). Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system. Brain Res Dev Brain Res 110: 135-158.
30. Hong CJ, Huo SJ, Liao DL, Lee K, Wu JY, Tsai SJ (2004). Case-control and family-based association studies between the neuregulin 1 (Arg38Gln) polymorphism and schizophrenia. Neurosci Lett 366: 158-161.
31. Iwata N, Suzuki T, Ikeda M, Kitajima T, Yamanouchi Y, Inada T et al (2004). No association with the neuregulin 1 haplotype to Japanese schizophrenia. Mol Psychiatry 9: 126-127.
32. Kendler KS, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F et al (1996). Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 153: 1534-1540.
33. Leroux-Nicollet I, Costentin J (1998). Transient expression of the vesicular monoamine transporter during development in the rat thalamus and cortex. Neurosci Lett 248: 167-170.
34. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I et al (2003). Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 73: 34-48.
35. Lewis DA, Levitt P (2002). Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 25: 409-432.
36. Li T, Stefansson H, Gudfinnsson E, Cai G, Liu X, Murray RM et al (2004). Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry 9: 698-704.
37. Liu CM, Hwu HG, Fann CS, Lin CY, Liu YL, Ou-Yang WC et al (2005). Linkage evidence of schizophrenia to loci near neuregulin 1 gene on chromosome 8p21 in Taiwanese families. Am J Med Genet B Neuropsychiatr Genet 134: 79-83.
38. Maier W, Hofgen B, Zobel A, Rietschel M (2005). Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes? Eur Arch Psychiatry Clin Neurosci 255: 159-166.
39. Manji HK, Lenox RH (2000). Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 48: 518-530.
40. Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, Ogata A et al (2003). Comparison of immunohistochemistry and real-time reverse transcription- polymerase chain reaction to detect expression of carcinoembryonic antigen in lung cancer. Oncol Rep 10: 1231-1235.
41. Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849-859 (discussion 863-864).
42. Ophoff RA, Escamilla MA, Service SK, Spesny M, Meshi DB, Poon W et al (2002). Genomewide linkage disequilibrium mapping of severe bipolar disorder in a population isolate. Am J Hum Genet 71: 565-574.
43. Park N, Juo SH, Cheng R, Liu J, Loth JE, Lilliston B et al (2004). Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol Psychiatry 9: 1091-1099.
44. Peter D, Finn JP, Klisak I, Liu Y, Kojis T, Heinzmann C et al (1993). Chromosomal localization of the human vesicular amine transporter genes. Genomics 18: 720-723.
45. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH (1995). Differential expression of two vesicular monoamine transporters. J Neurosci 15: 6179-6188.
46. Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR et al (2005). Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 10: 328.
47. Potash JB, Chiu YF, MacKinnon DF, Miller EB, Simpson SG, McMahon FJ et al (2003). Familial aggregation of psychotic symptoms in a replication set of 69 bipolar disorder pedigrees. Am J Med Genet B Neuropsychiatr Genet 116: 90-97.
48. Potash JB, Willour VL, Chiu YF, Simpson SG, MacKinnon DF, Pearlson GD et al (2001). The familial aggregation of psychotic symptoms in bipolar disorder pedigrees. Am J Psychiatry 158: 1258-1264.
49. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blouin JL et al (1995). Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes. Am J Med Genet 60: 252-260.
50. Pulver AE, Mulle J, Nestadt G, Swartz KL, Blouin JL, Dombroski B et al (2000). Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes. Mol Psychiatry 5: 650-653.
51. Roghani A, Welch C, Xia Y, Liu Y, Peter D, Finn JP et al (1996). Assignment of the mouse vesicular monoamine transporter genes, Slc18a1 and Slc18a2, to chromosomes 8 and 19 by linkage analysis. Mamm Genome 7: 393-394.
52. Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger Jr JI et al (2003). Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 73: 49-62.
53. 125I]2-N-[(3′-iodo-4′- azidophenyl)propionyl] tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J Biol Chem 272: 26049-26055.
54. Slattery DA, Hudson AL, Nutt DJ (2004). Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 18: 1-21.
55. Smoller JW, Finn CT (2003). Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 123: 48-58.
56. Spielman RS, Ewens WJ (1996). The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet 59: 983-989.
57. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E et al (2003). Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 72: 83-87.
58. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S et al (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71: 877-892.
59. Straub RE, MacLean CJ, Walsh D, Kendler KS (1996). Support for schizophrenia vulnerability loci on chromosomes 6p and 8p from Irish families. Cold Spring Harb Symp Quant Biol 61: 823-833.
60. Suarez BK, Duan J, Sanders AR, Hinrichs AL, Jin CH, Hou C et al (2006). Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. Am J Hum Genet 78: 315-333.
61. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ et al (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 113: 1353-1363.
62. Tamminga CA, Holcomb HH (2005). Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 10: 27-39.
63. Tang JX, Chen WY, He G, Zhou J, Gu NF, Feng GY et al (2004). Polymorphisms within 50 end of the neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population. Mol Psychiatry 9: 11-12.
64. Thiselton DL, Webb BT, Neale BM, Ribble RC, O'Neill FA, Walsh D et al (2004). No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). Mol Psychiatry 9: 729.
65. Verney C, Lebrand C, Gaspar P (2002). Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter. Anat Rec 267: 87-93.
66. Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, Zammit S et al (2003). Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry 8: 485-487.
67. Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL et al (2003). Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry 8: 706-709.
68. Zubieta JK, Huguelet P, Ohl LE, Koeppe RA, Kilbourn MR, Carr JM et al (2000). High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry 157: 1619-1628.
69. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA (2001). Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 49: 110-116.